A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

Completed · Phase 1

Conditions studied: Brain Neoplasms, Glioma, Medulloblastoma

In brief

The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the maximum tolerated dose of RMP-7 in children with refractory brain tumors.

Key facts

Study ID
NCT00001502
Run by
National Cancer Institute (NCI)
People needed
30
Starts
1996-04-01
Expected to finish
2000-03-01
Last updated by the study team
2008-03-04

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.